Dr. Pamela M. Santamaria, MD

Dr. Santamaria practices at Neurology Consultants of Nebraska in Omaha, Nebraska.

Dr. Santamaria's NPI, 1083693287, was assigned on January 16, 2006. Dr. Santamaria graduated from University of Iowa, RJ & L Carver College of Medicine in 1998. Dr. Santamaria holds Nebraska license 22135.

Dr. Santamaria's primary practice is Neurology Consultants of Nebraska, at 4242 Farnam St, Omaha, NE 68131 in Douglas County. The practice phone is (402) 552-2650.

Dr. Santamaria's primary practice is Neurology Consultants of Nebraska in Omaha, Nebraska. Dr. Santamaria is also affiliated with Nebraska Medical Center. The medical group on file is Neurology Consultants of Nebraska. Dmand AI also links Dr. Santamaria to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Santamaria practices, 6 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Santamaria's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Santamaria is licensed in Nebraska.

CMS data shows 22,040 Medicare services from Dr. Santamaria across 9 procedure codes in 2024, for 314 Medicare patients. Medicare paid $162,092 for them. Every service was in an office.

CMS counts 314 Medicare patients who saw Dr. Santamaria in 2024. The largest group is 65 to 74, with 129 patients. 64% of them have high cholesterol, and 60% have high blood pressure. 18% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Santamaria's median patient age at 65, with 63% women.

In 2024, Dr. Santamaria wrote 4,182 Medicare Part D claims for 414 patients. 85% of them were for generic drugs. CMS names the drug for 3,770 of them, across 90 drugs with 11 or more claims each, at $1,848,687 in total drug cost. In 2023, CMS named 3,234 claims across 86 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 0 out of 100 for Dr. Santamaria for performance year 2024, reported individually. Dr. Santamaria accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Santamaria as offering telehealth.

Dmand AI links 9 papers to Dr. Santamaria, published from 2012 to 2023. 2016 was the busiest year, with 2. The most frequent topics are Parkinson Disease, Magnetoencephalography and Movement. Dr. Santamaria has published most often in Neuroimage Clin. Dr. Santamaria's most frequent co-authors are David G. Standaert, John M. Bertoni, MD, PhD and Danish Ejaz Bhatti, MBBS.

Dmand AI links Dr. Santamaria to 1 clinical trial. Conditions studied include Delusions and Hallucinations. Open Payments lists research payments to Dr. Santamaria that name 1 trial.

CMS Open Payments shows 3,143 general payments to Dr. Santamaria from 89 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 70% of the total. Biogen, Inc. paid the most, $76,618. It also lists 6 research payments totaling $12,500 from 2019 to 2020, naming 1 clinical trial.

Dr. Santamaria graduated from University of Iowa, RJ & L Carver College of Medicine in 1998.